Find a Clinical Trial

Filter Results By

  • Postal Code
  • Country
  • Trial Status
  • Type of Trial
  • Diagnosis

Sort by Trial name

Active Trials in Locations

Enter your Postal Code to find the nearest trial.

Sorry, that criteria does not currently fit any trials.

Currently Enrolling
Interventional

FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with:

• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)

See also the EPPIK Clinical Study for Children with FSGS and MCD.

Learn More
Currently Enrolling
Interventional

FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with:

• Focal segmental glomerulosclerosis (FSGS)
• Minimal change disease (MCD)

See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.

Learn More
Currently Enrolling
Interventional

The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN1210 also known as ravulizumab or ULTOMIRIS ®) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

Learn More
Currently Enrolling
Interventional

The study is evaluating the safety and effectiveness of an investigational, targeted C3 inhibitor called pegcetacoplan in adults who have C3G or IC-MPGN recurrence after kidney transplant

Learn More
Currently Enrolling
Interventional

The purpose of this study is to assess the efficacy and safety of twice weekly pegcetacoplan compared to placebo in patients with C3G or IC-MPGN, on the basis of a reduction in urinary protein levels.

Learn More
Currently Enrolling
Interventional

This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.

Learn More
Currently Enrolling
Interventional

The ADU-CL-19 study is testing BION-1301, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.

Learn More
Currently Enrolling
Interventional

The AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and diabetic kidney disease.

Learn More
Currently Enrolling
Interventional

The ALIGN study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.

Learn More
Currently Enrolling
Observational

Cure Glomerulonephropathy (CureGN) is a multicenter five-year observational study of glomerular disease patients.

Learn More
Currently Enrolling
Observational

The Laboratory of Inherited Kidney Disease at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts, directed by Dr. Martin Pollak, seeks to identify genes that underlie the development of FSGS and similar diseases.

Learn More
Currently Enrolling
Interventional

GFB-887-201 is an interventional study comparing GFB-887 to placebo in patients with focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), and diabetic nephropathy (DN).

Learn More
Currently Enrolling
Interventional

Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.

The study is ongoing at pediatric sites.

Learn More
Currently Enrolling
Interventional

Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.

Learn More
Enrollment Closed
Interventional

The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.

Learn More
Currently Enrolling
Observational

The purpose of this study is to gather long-term observational data in order to help understand the biology behind nephrotic syndrome.

Learn More
Enrollment Closed
Interventional

The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adults with FSGS. The intention is to evaluate study drug safety, as well as to obtain an early indication of effectiveness (how well the study drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage).

Learn More
Currently Enrolling
Interventional

IgA nephropathy, also known as Berger’s Disease, is a kidney disease in which IgA, a protein meant to help the body fight infections, accumulates in the kidneys and damages them. This study is seeking to determine the safety and effectiveness of Telitacicept in the treatment of IgA nephropathy. A clinical study using this investigational new drug in China showed potential benefit in treating IgAN by reducing urine protein. However, more clinical data is needed to further evaluate the effectiveness and safety of Telitacicept in IgAN patients.

Learn More
Currently Enrolling
Observational

The Rare Genomes Project aims to increase rare and undiagnosed families’ access to genomic research, empowering patients to directly accelerate the pace of rare disease diagnosis. This project was designed to be a direct partnership between researchers and patients, so we can better understand their conditions.

Learn More
Currently Enrolling
Observational

The TANGO study aims to create a large international network of centers to study glomerular disease (GN) recurrence after renal transplantation.

Learn More
Currently Enrolling
Interventional

This study is a Phase 1b/2a, open‑label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN. The study consists of 2 phases (dose escalation and dose expansion). Each subject may receive maintenance dosing at 6 months following the initial dose, if certain safety and PD criteria are met.
In the dose escalation phase, subjects will receive 2 bi-weekly doses of VB119 at the specified dose level, administered via intravenous (IV) infusion. After the first dose cohort (100 mg administered every 14 days for 2 doses, 200 mg cumulative dose), subjects in subsequent cohorts may receive 4 weekly doses rather than 2 bi-weekly doses, per determination by the Data Review Committee (DRC). The decision to shift to weekly dosing will rely on accumulating safety data and the onset and durability of B cell depletion effects.

Learn More
Currently Enrolling
Interventional

The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.

Learn More
Enrollment Closed
Interventional

This clinical research study is investigating a potential treatment option for adults of African or Caribbean descent with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Testing for the APOL1 gene is included in this clinical study.

Learn More
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

Still have questions?
See other frequently asked questions
Did you know that some forms of kidney disease can be genetic?Researchers are continually discovering genetic causes of Nephrotic Syndrome.

Learn more about genetic causes of kidney disease and find out if you may be affected.